Journal profile · Medicine-Oncology
JAMA Oncology
ISSN 2374-2445 · American Medical Association · UNITED STATES
JAMA Oncology: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 23.19; hybrid open access; review about 3 days (submission to first decision, publisher); acceptance rate 8% (journal website); 337 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
JAMA Oncology is published by American Medical Association and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations and Economic and Financial Impacts of Cancer, together about 22.1% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
JAMA Oncology is committed to publishing influential original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients with cancer. Impact and Reach Journal Impact Factor of 23.9, one of the highest ranking among oncology journals Broad reach through related commentary, author audio interviews, podcasts, email alerts, multimedia, and more than 139,000 social media followers (Facebook, X, LinkedIn) More than 7.6 million annual article views and downloads International authors: 61% of submissions come from outside the United States Extensive press coverage: In 2025 and 2026, JAMA Oncology received more than 7,300 mentions in over 1,800 outlets consisting of news media, broadcast TV and radio stations, blogs, news aggregators, and more Top Altmetric scores—JAMA Oncology published 21 of the top 50 articles among oncology journals, including the No. 1 article Number of citations, Altmetric score, page views, and PDF downloads tracked for your published article Prompt Decisions and Rapid Publication Timelines Highly selective peer review and editorial evaluation, with 8% acceptance rate for all submissions Median time to first decision: 3 days without external peer review; 32 days with review Expedited peer review and online publication for select clinical trials, other major studies, or reports with urgent public health importance Online First publication of all major articles Coordination with meeting presentation: Opportunity to publish new research simultaneously with your presentation Author Service User-friendly manuscript submission system and process Prompt, expert review and consideration from our experienced editors Highest standards followed to improve your accepted manuscript’s accuracy, reliability, and readability CME credit available for lead authors who publish in JAMA Oncology Opportunity for your work to be augmented with expert illustration, interactive features, video, audio, and visual abstract Display of content on fast, device-responsive website Citations, views, and Altmetric score displayed with every article Free public access: All research articles are freely available 12 months after publication on the journal's website Open access: Authors of research articles may elect to pay for immediate open access on the day of publication Deposit to PubMed Central: The journal deposits all published research articles into PubMed Central (PMC) for authors Authors may post the accepted version
From the journal's Aims & Scope
Research area (LetPub): Medicine-Oncology
Editor-in-chief Mary L. (Nora) DisisPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine7.6%
- Lung Cancer Treatments and MutationsMedicine7.6%
- Economic and Financial Impacts of CancerEconomics, Econometrics and Finance6.9%
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology6.1%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology5.9%
- Health Systems, Economic Evaluations, Quality of LifeEconomics, Econometrics and Finance5.2%
- Prostate Cancer Treatment and ResearchMedicine4.8%
- Global Cancer Incidence and ScreeningMedicine4.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PubMedPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 23.19LetPub ·
- Impact factor (publisher)
- 23.9Publisher website ·
- CiteScore 2026-06
- 32.6LetPub ·
- SJR 2026-06
- 7.4LetPub ·
- SNIP 2026-06
- 5.31LetPub ·
- h-index
- 41LetPub ·
- h-index
- 248OpenAlex ·
- i10-index
- 2,031OpenAlex ·
- 2-year mean citedness
- 8.48OpenAlex ·
- Self-citation rate
- 1.7%LetPub ·
- Share of gold OA articles
- 26.58%LetPub ·
Volume
- Articles per year
- 109LetPub ·
- Downloads per year (publisher) 2024
- 7,600,000Publisher website ·
Articles by year OpenAlex count · 4,881 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 245 | 97 | 244 |
| 2025 | 337 | 155 | 2,087 |
| 2024 | 383 | 187 | 5,851 |
| 2023 | 362 | 190 | 11,365 |
| 2022 | 418 | 218 | 13,523 |
| 2021 | 419 | 219 | 21,508 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Acceptance rate (publisher)
- 8%Publisher website ·
- Desk decision 2024
- 3 daysPublisher website ·
- Submission to first decision
- 3 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
Other charges and waivers (author guidelines)
- Page charges
- Charged; see the journal's website for the amount
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted1
- reviewReviewLength not stated
Policy excerpts from the journal's websiteOpen access, Self-archiving
- Open access
Free access to all research articles 12 months after publication. Model summary
All research articles are made free access online 12 months after publication on the website.
Source ↗Publisher website ·- Self-archiving
Automatic deposit of all published research articles into PubMed Central. Model summary
The journal deposits all published research articles into PubMed Central (PMC) for authors
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- American Medical Association
- Country or region
- UNITED STATES
- Language
- English
- ISSN
- 2374-2445
- Print ISSN
- 2374-2437
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about JAMA Oncology
What CAS zone is JAMA Oncology in?
In the 2025 upgraded edition of the CAS Journal Ranking, JAMA Oncology is in Zone 1 of Medicine, and in Zone 1 of the minor category Oncology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of JAMA Oncology?
The latest impact factor listed by LetPub is 23.19; CiteScore 32.6, h-index 248.
How long does peer review take at JAMA Oncology?
The publisher reports about 3 days (submission to first decision); first decisions include desk rejections; the journal's website gives an acceptance rate of 8%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index JAMA Oncology?
According to LetPub and DOAJ records, JAMA Oncology is indexed in SCIE and Scopus. The journal's website also lists PubMed; that list has not been checked against each database.
Is JAMA Oncology open access, and what is the APC?
JAMA Oncology is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .